Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 3-year extension of subcutaneous AIN457 in active lupus nephritis
CTR20223330Phase 3Terminated
- Sponsor
- Novartis
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of secukinumab in lupus nephritis (LN), sponsored by Novartis. Started Dec 2022; status: terminated.
02
Drugs
secukinumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20223330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223330.